stem-cell] researchers and to the progression of research, " says Pederson. "That's the hurricane.
That's what's doing the damage. "
Andrew Elefanty, a stem-cell scientist at Monash University in Melbourne, Australia, says that if the US situation is not speedily resolved it will affect his work. Elefanty is an expert in producing stem-cell lines labelled with fluorescent 'reporter' genes, which are useful for identifying specific cell types as they differentiate in vitro. Since 2008, 13 of the 21 international research collaborations that Elefanty and his lab co-chief Ed Stanley have established or are in the process of establishing are with groups in the United States. "Our concern is that uncertainty in the United States will limit our ability to collaborate, which then has knock-on effects on the quality of work we can put out. We depend on a lot of those collaborators to do really good science, " says Elefanty.
The funding freeze may affect some foreign scientists directly; they are eligible to win NIH grants if no American is doing the same work. Andrew Laslett, a stem-cell scientist at the Commonwealth Scientific and Industrial Research Organisation in Melbourne, was paid as a postdoc for three years from a large, collaborative NIH grant to derive kidney progenitor cells from human embryonic stem cells.
"That grant really set me on my career. It introduced me to the people I am still collaborating with today, and led me to getting my first independent grant, " says Laslett. The news of some of those collaborators in the United States now losing funding "made me cringe", he adds.
A further layer of uncertainty hangs over foreign postdocs working in the United States who must now consider whether to remain in the country. "It's kind of all sinking in at the moment, " says Adam Goulburn, who earned his PhD in Elefanty's lab and started a postdoc at Weill Cornell Medical College in New York last month. Working in the lab of Stewart Anderson, Goulburn is trying to derive pure populations of interneurons from human embryonic stem cells. The improper migration and function of these cells in the developing brain has been implicated in diseases including autism, epilepsy and schizophrenia. Goulburn's project is not immediately threatened, but the private seed money supporting him today will ultimately require scaling up with NIH funds. Anderson says that if the injunction stands, his ability to fund Goulburn's project in the long run will probably be impaired.
In the future, "highly talented, well-trained stem-cell researchers from abroad, like Adam, Court ruling endangers international partnerships. This alters the legal landscape around the issue and means that the wording of the DeGette bill will probably need to be modified.
US stem-cell chaos felt abroad
"I think it would have to have some additional language" to deal with the Dickey-Wicker Amendment, says Richard Hynes, a stem-cell researcher at the Massachusetts Institute of Technology in Cambridge who is closely involved in the policy side of the field. "It didn't have to before, because nobody thought it was necessary."
Others have raised concerns that the bill's current wording could fuel opponents' arguments against its passage. Louis Guenin, a philosopher of science at Harvard Medical School in Boston, Massachusetts, says that the bill does not specifically exclude funding to derive stem-cell lines, which puts it at odds with the presidential order, and does not restrict the use of stem cells to medical research and therapy. He has proposed a modified version of the bill, which addresses these and other issues.
"I think all of us have been trying to understand what is politically feasible," says George Daley, a stem-cell researcher at the Children's Hospital Boston in Massachusetts. A survey by the research advocacy group Research!America in August found that 70% of Americans support expanded federal funding for embryonic stem-cell research, but political realities suggest that DeGette's bill could still be in for a rocky ride.
At present, polls indicate that the Democrats may lose their majority in the House of Representatives in mid-term elections this November. A stemcell bill could pass before then, but it is unclear whether bipartisan support can be mustered to move the legislation forward. During the previous two votes, a small number of Republican 'yea' votes were important in getting the bill passed (see 'How the votes were cast').
Once the election is over, the current Congress could still pass a bill before it adjourns in 2011. If a House-bill passes, a parallel bill would then have to be introduced and passed in the Senate. Senator Tom Harkin (Democrat, Iowa), who co-sponsored and introduced stem-cell bills vetoed by Bush, will hold a hearing on 16 September to examine the broad impact of last month's injunction.
Lawmakers "are still figuring out "what to move forward with, but there's a sense of urgency", says Juliet Johnson, a spokeswoman for DeGette's office. Other supporters in Congress agree. "I believe the recent court ruling only re-energizes the efforts of lawmakers like myself to develop bipartisan legislation that allows us to move forward without delay," says Representative Mark Kirk (Republican, Illinois).
